5 November 2024, Tue |
6:57 PM
Novartis will exhibit the most promising frontiers of science at Expo 2020. With Expo 2020 Dubai, the world’s largest exhibition, just around the corner, Novartis, a worldwide medical company, will make an appearance at the Swiss Pavilion located in the Opportunity District during the opening month of Expo 2020 Dubai. Novartis pledges to highlight the most promising scientific areas, the most revolutionary medical advances, and the most pressing healthcare needs.
Novartis will bring together four vital pillars that will be presented to visiting guests, esteemed press, authorities, and the general public at their experiential exhibition, highlighting Data Science and Artificial Intelligence, Cell and Gene Therapy, Building Trust with Society, and Patient Community. Novartis employs creative science and digital technology to deliver transformative treatments in areas of great medical need, and the Swiss corporation will highlight its four primary pillars of strength over the month of October.
Georg Schroeckenfuchs [President and Head MEA Cluster, Novartis] commented: “With Novartis’ ongoing journey of research and development, we have partnered with the Swiss Pavilion during the first month of Expo 2020 Dubai to showcase our companies’ latest and most transformative innovations in medicine. We aim to hold ourselves to the highest standards of sustainability and ethical business practices and to build trust with society. In the long run, that’s what will enable us to continue reimagining medicine by addressing the needs of our patients and using innovative technologies to create transformative medical treatments.”
During Novartis’ presence at Expo 2020 Dubai, they will present four pillars:
Novartis has been on a journey to become the world’s leading medicines firm, fueled by data science and digital technologies, from its inception. Novartis is committed to integrating data science and digital technology into drug discovery (R&D) and health care delivery. Another key feature of Novartis is Artificial Intelligence (AI), which provides a welcoming environment in which to develop, test, and expand AI-based solutions. Novartis wants to change how they develop innovative medications, communicate with patients, health care providers, and healthcare systems, and improve operational efficiency with its partners.
Novartis is developing innovative medicines in a variety of disease categories and developing new technological platforms, such as cell and gene therapies and radioligand therapeutics. Novartis is dedicated to developing and delivering access to gene treatments to patients and families affected by rare and life-threatening genetic illnesses. Rather than simply managing symptoms, cell and gene therapies are designed to stop or reverse disease progression. These are usually one-time treatments that can help to alleviate the underlying cause of an illness and even cure certain ailments.
Novartis takes great responsibility and even greater opportunity to lead the world in creating positive social change by embracing societal impact as a core business objective, as defined by their corporate strategy, which defines their focus areas for managing environmental, social, and corporate governance topics. Novartis takes an integrated approach across these global efforts and continues on a journey to create a culture in which these activities are deeply rooted in their daily work by being part of the solution on pricing and access, tackling global health challenges, being a responsible citizen, and holding themselves to high ethical standards.
Novartis is committed to engaging with its global patient community to discover new methods to improve and prolong people’s lives. Novartis can enhance patient outcomes and revolutionise medical practise by working together. Every day, Novartis recognizes the importance of patients and caregivers, as well as their understanding of what to expect from the company, as they commit to actively seek out and listen to patient insights, bolstering their commitment to using science-based innovation to address some of society’s most difficult healthcare issues.
Mohamed EzzEldin [President and Gulf Cluster Head, Novartis] also said: “As we are honored to be exhibiting our brand attributes in our home country pavilion, not only was Switzerland the first nation to confirm its participation at Expo 2020 Dubai, but Novartis was the first Swiss company to confirm its appearance at the Swiss Pavilion during this mega event. We are excited to help turn the spotlight on Swiss innovation and the products and services as a private-sector partner, to help promote the country’s economic capacity and attractiveness as a tourist destination to the UAE − Switzerland’s foremost trading partner in the Middle East. A nation of scientists, with a passion in natural science and medicine.”
Wael Omran [Oncology General Manager Gulf, Novartis] also added: “The Swiss pavilion revolves around reflecting key aspects of Switzerland’s culture, natural beauty and innovations, delivered through a series of interactive elements and images; the country’s breathtaking landscapes serving as a backdrop to Swiss solutions for a sustainable future, showcasing Swiss technologies, innovations and scientific achievements. Novartis’ exhibit will showcase our frontier technology emphasizing on a positive impact, aspiring all our guests to be entertained by.”
Marie-Andree Gamache [Oncology Head MEA Cluster, Novartis] commented: “With innovation being at the heart of Novartis, we will be showcasing the most promising frontiers of science. We strive to engage with our visiting guests and our patient community to give back to the society through education, knowledge and meeting significant healthcare needs. Patients are at the center of everything we do, and by consistently gaining insights on their needs, we focus on improving and prolonging life.”
Vijay Zutshi [Head of Gulf and Levant at Sandoz (a Novartis Division)] also added: “As a patient and science-focused organization, we are always prepared with business continuity plans that are so critical for a company like ours. Importantly, right now in this day and age, we are focused on the safety of our patients, their caregivers and the health care professionals providing care, and continuation of treatment protocols for our patients. As a patient-focused company whose mission is to save and improve lives, we are keeping our doors open so we can ensure that no patient is left behind in therapeutic areas.”
